REGENXBIO Inc. (NASDAQ:RGNX) Given Average Rating of "Moderate Buy" by Analysts

Shares of REGENXBIO Inc. (NASDAQ:RGNX - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the twelve ratings firms that are currently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a hold rating and eleven have issued a buy rating on the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $35.27.

Several equities analysts have recently weighed in on RGNX shares. HC Wainwright cut their target price on shares of REGENXBIO from $40.00 to $36.00 and set a "buy" rating for the company in a report on Thursday, November 21st. Chardan Capital restated a "buy" rating and set a $52.00 price target on shares of REGENXBIO in a research report on Wednesday, November 20th. Morgan Stanley restated an "overweight" rating and set a $22.00 price target on shares of REGENXBIO in a research report on Friday, November 15th. Royal Bank of Canada restated an "outperform" rating and set a $35.00 price target on shares of REGENXBIO in a research report on Wednesday. Finally, Raymond James restated an "outperform" rating and set a $18.00 price target on shares of REGENXBIO in a research report on Thursday, October 10th.

REGENXBIO Stock Performance

REGENXBIO stock traded down $0.58 during midday trading on Thursday, hitting $8.72. 1,134,413 shares of the company were exchanged, compared to its average volume of 655,190. REGENXBIO has a fifty-two week low of $8.44 and a fifty-two week high of $28.80. The firm has a market capitalization of $432.03 million, a PE ratio of -1.73 and a beta of 1.24. The business has a fifty day simple moving average of $9.77 and a two-hundred day simple moving average of $11.47.

Insider Buying and Selling

In other REGENXBIO news, Director Argeris N. Karabelas sold 10,000 shares of REGENXBIO stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $10.11, for a total transaction of $101,100.00. Following the sale, the director now owns 11,286 shares of the company's stock, valued at $114,101.46. The trade was a 46.98 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 13.13% of the stock is owned by company insiders.

Institutional Investors Weigh In On REGENXBIO

Several institutional investors and hedge funds have recently added to or reduced their stakes in RGNX. FMR LLC boosted its stake in REGENXBIO by 166.8% during the 3rd quarter. FMR LLC now owns 2,649 shares of the biotechnology company's stock worth $28,000 after purchasing an additional 1,656 shares during the last quarter. nVerses Capital LLC boosted its stake in REGENXBIO by 183.3% during the 3rd quarter. nVerses Capital LLC now owns 3,400 shares of the biotechnology company's stock worth $36,000 after purchasing an additional 2,200 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its stake in REGENXBIO by 64.3% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,506 shares of the biotechnology company's stock worth $100,000 after purchasing an additional 3,720 shares during the last quarter. Diversified Trust Co acquired a new stake in REGENXBIO during the 2nd quarter worth $121,000. Finally, Arizona State Retirement System boosted its position in shares of REGENXBIO by 20.6% during the 2nd quarter. Arizona State Retirement System now owns 11,669 shares of the biotechnology company's stock valued at $137,000 after acquiring an additional 1,997 shares during the last quarter. Institutional investors and hedge funds own 88.08% of the company's stock.

About REGENXBIO

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.